Immunomedics, Inc. (NASDAQ:IMMU) has earned a consensus rating of “Buy” from the seven analysts that are covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $21.00.

IMMU has been the topic of a number of research reports. BidaskClub upgraded shares of Immunomedics from a “hold” rating to a “buy” rating in a report on Friday, December 22nd. Jefferies Group boosted their target price on shares of Immunomedics from $22.00 to $27.00 and gave the company a “buy” rating in a report on Wednesday, January 24th. TheStreet upgraded shares of Immunomedics from a “d” rating to a “c-” rating in a report on Friday. Zacks Investment Research cut shares of Immunomedics from a “buy” rating to a “hold” rating in a report on Wednesday, November 15th. Finally, ValuEngine upgraded shares of Immunomedics from a “sell” rating to a “hold” rating in a report on Friday, February 2nd.

Shares of Immunomedics (NASDAQ IMMU) traded up $0.02 during mid-day trading on Friday, hitting $15.13. 2,201,200 shares of the stock were exchanged, compared to its average volume of 2,568,183. Immunomedics has a 1 year low of $4.73 and a 1 year high of $18.93. The company has a market cap of $2,504.99, a PE ratio of -7.49 and a beta of 1.50. The company has a current ratio of 1.26, a quick ratio of 1.26 and a debt-to-equity ratio of 1.20.

In related news, insider Behzad Aghazadeh purchased 1,325,000 shares of the stock in a transaction dated Wednesday, November 15th. The stock was purchased at an average price of $10.47 per share, with a total value of $13,872,750.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Brian A. Markison sold 8,390 shares of Immunomedics stock in a transaction dated Monday, November 20th. The stock was sold at an average price of $11.89, for a total value of $99,757.10. Following the completion of the transaction, the director now directly owns 99,178 shares of the company’s stock, valued at approximately $1,179,226.42. The disclosure for this sale can be found here. Insiders own 6.60% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Amalgamated Bank raised its position in shares of Immunomedics by 8.1% in the 2nd quarter. Amalgamated Bank now owns 12,911 shares of the biopharmaceutical company’s stock worth $114,000 after purchasing an additional 966 shares during the last quarter. Raymond James Financial Services Advisors Inc. raised its position in shares of Immunomedics by 11.4% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 14,400 shares of the biopharmaceutical company’s stock worth $127,000 after purchasing an additional 1,473 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in shares of Immunomedics by 2.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 79,520 shares of the biopharmaceutical company’s stock worth $702,000 after purchasing an additional 1,763 shares during the last quarter. Voya Investment Management LLC raised its position in shares of Immunomedics by 5.9% in the 2nd quarter. Voya Investment Management LLC now owns 50,433 shares of the biopharmaceutical company’s stock worth $445,000 after purchasing an additional 2,808 shares during the last quarter. Finally, Alliancebernstein L.P. raised its position in shares of Immunomedics by 2.4% in the 2nd quarter. Alliancebernstein L.P. now owns 178,198 shares of the biopharmaceutical company’s stock worth $1,573,000 after purchasing an additional 4,200 shares during the last quarter. 75.95% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This report was originally published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this report on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this report can be viewed at https://theolympiareport.com/2018/02/13/immunomedics-inc-immu-receives-21-00-average-price-target-from-brokerages.html.

About Immunomedics

Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.

Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.